कंपनी का अवलोकन
Clover Health Investments, Corp. operates primarily within the United States by offering Medicare Advantage plans tailored for Medicare-eligible individuals. The corporation functions specifically within the Healthcare sector and the Healthcare Plans industry, providing preferred provider organization and health maintenance organization plans to its target demographic. In terms of scale, the company maintains a market capitalization of $1.00B with an annual revenue of $1.92B and employs a workforce of 724 individuals. These valuation and revenue figures indicate that while the entity holds a significant market presence valued at one billion dollars, its financial operations generate nearly two billion dollars in annual sales, positioning it as a substantial player in the specialized Medicare insurance landscape despite its relatively lean employee base.
वित्तीय स्वास्थ्य
The company reported a revenue of $1.92B for the trailing twelve months, yet recorded a net income of $-85,549,000 and an EBITDA of $-85,343,000. The substantial gap between the $1.92B revenue and the negative net income reveals a cost structure where operating expenses significantly exceed gross profit generation, resulting in a loss before interest and taxes. Free cash flow stands at $-35,821,624, which indicates that the company is currently consuming cash rather than generating it, thereby limiting immediate financial flexibility for external expansion without additional capital infusion. The gross margin is 18.5%, suggesting that for every dollar of revenue, 18.5 cents remain after the direct costs of providing healthcare services. The operating margin is -10.1% and the profit margin is -4.4%, reflecting high operational burn rates and the difficulty of converting revenue into bottom-line profit in this specific business model. On the balance sheet, the company holds $120.26M in cash against $0 in debt, meaning the firm is not leveraged but relies entirely on its cash reserves to fund operations. The debt-to-equity ratio is N/A due to the absence of debt, and the current ratio of 1.47 indicates that the company possesses sufficient current assets to cover its short-term liabilities, ensuring reasonable short-term liquidity. Return on Equity is -26.3% and Return on Assets is -9.5%, which reveals that management is currently generating negative returns on both shareholder equity and the total asset base, signaling that the existing capital deployment is not yet yielding profitable outcomes.
मूल्यांकन आकलन
The trailing P/E ratio is N/A because the company reports a net loss, while the forward P/E is 21.22, implying that the market expects earnings to turn positive in the future to justify a price multiple based on anticipated future profitability. The price-to-book ratio is 3.21, indicating that the market values the company at more than three times its book value, which suggests a premium placed on its intangible assets or growth potential despite current losses. The price-to-sales ratio is 0.52 and the EV/EBITDA is -10.33, suggesting that valuation is being driven by revenue growth rather than current earnings power, as negative EV/EBITDA typically reflects a company that is burning cash relative to its enterprise value. The 52-week high is $3.92 and the 52-week low is $1.58; without a specific current price provided in the facts, the range establishes a volatility corridor where the stock price has fluctuated significantly over the last year. The beta is 2.25, which means the stock is expected to be 125% more volatile than the broader market, exposing investors to substantial price swings during periods of market turbulence.
Growth & Income
Revenue growth year-over-year is 44.7%, while earnings growth is N/A due to the current unprofitable status, implying that top-line expansion is occurring without a corresponding increase in net income at this stage. Since the company does not pay dividends, indicated by a dividend yield of N/A and a payout ratio of 0.0%, it is not distributing earnings to shareholders as the earnings are currently negative. Consequently, the company reinvests its resources, including its $120.26M cash balance, back into the business to fund operations and support the aggressive 44.7% revenue expansion rather than paying out income. The overall growth and income profile is characterized by rapid revenue acceleration accompanied by significant cash burn and no dividend income, reflecting a high-risk, high-reward investment strategy typical of early-stage growth companies in the healthcare sector.